Dear Dr. Roach • I am an 80-year-old woman who always had excellent health until about four years ago, when I was diagnosed as having developed bronchiectasis. Since then, I have had to use an ...

Abiraterone is a CYP17A1 inhibitor that improves survival in castration-resistant prostate cancer (CRPC). Abiraterone is licensed in combination with prednisone 5 mg twice daily to prevent a syndrome ...

CHICAGO — Although improvements were seen in PFS, bevacizumab in combination with docetaxel and prednisone did not improve OS in men with metastatic castration-resistant prostate cancer. In fact, the ...

Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer RARITAN, N.J., ...

PURPOSE: Time to progression (TTP), overall survival, and quality of life (QL) were compared in patients with hormone-resistant prostate cancer (HRPC) treated with prednisone (5 mg orally, four times ...

ZYTIGA(R) Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer ...

Five-year results from the extended randomized MGTX trial demonstrated that the addition of thymectomy to prednisone leads to long-lasting lower quantitative myasthenia gravis (QMG) scores and ...

A phase II randomized study of cixutumumab (IMC-A12: CIX) or ramucirumab (IMC‐1121B: RAM) plus mitoxantrone (M) and prednisone (P) in patients (pts) with metastatic castrate-resistant prostate cancer ...

Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dear Dr. Roach • I am an 80-year-old woman who always had excellent health until about four years ago, when I was diagnosed as ...

Phase 3 Results Show Significant Improvement in Radiographic Progression-Free Survival and a Trend for Increased Overall Survival in Patients Receiving ZYTIGA Plus Prednisone CHICAGO, June 2, 2012 ...